General MedicationsINTRAVENOUSStandard
POLIVY
POLATUZUMAB VEDOTIN-PIIQ
Standard Dose
30MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview POLIVY is listed in Drugs@FDA under application 761121 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient POLATUZUMAB VEDOTIN-PIIQ Form and strength POWDER;INTRAVENOUS - 30MG/VIAL Sponsor GENENTECH Submission history Latest submission status date: 2026-03-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview POLIVY is listed in Drugs@FDA under application 761121 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient POLATUZUMAB VEDOTIN-PIIQ Form and strength POWDER;INTRAVENOUS - 30MG/VIAL Sponsor GENENTECH Submission history Latest submission status date: 2026-03-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.